Medical CBRN Defense Consortium (MCDC) Other Transaction Agreement (OTA) Request for Information (RFI) – CoV Pandemic Response
The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense’s (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.
Subsidy: no limit (This request is Market Research to determine the capability of the industrial base to respond to the 2019-nCoV pandemic. At this time, funding has not been identified for any prototype projects under this request).
Project duration: 1-6 months, dependently on the area of focus (longer projects are NOT requested)Consortium: Submission is open to all entities of the US Defense Industrial Base, not just MCDC members. Should a non-MCDC member be selected for award, that entity would be required to join the MCDC prior to award execution. Foreign firms with no US-based affiliate are also eligible (send your submission directly email@example.com and we will upload your submission).
Scope: Obtain information via White Papers in response to the novel Coronavirus (2019-nCoV) pandemic in the United States (U.S.). The Government is requesting White Papers with a focus on the following areas:
- Diagnostics/Monitoring: Medical diagnostic devices, with specific emphasis on Point-of-Care diagnostics (e.g. CLIA waived), under development and capable of diagnosing 2019- SARS-CoV-2, within 1-4 months
- Surveillance: Surveillance methods and associated devices for 2019-SARS-CoV-2 screening.
- Information systems and technology the Government can use in a handheld Point-of-Care device to collect, screen, collate, report, and monitor disease infection and pandemic spread on a micro and macro level.
- Therapeutics: Drugs and/or drug/device combinations, or platforms currently under development demonstrating efficacy in post-exposure, pre- and post-symptomatic studies for any CoV strain, and capable of achieving EUA from the FDA within the next three (3) months for this ongoing SARS-CoV-2 pandemic.
- Prophylactics: Drugs or vaccines currently under development demonstrating pre-exposure in vivo efficacy or in vitro activity against any or all strains of CoV. Antibody technology, accelerating the discovery, development, manufacturing and prediction of success for these technologies can be considered.
- Clinical Trials: Opportunities to expeditiously conduct clinical trials for any technology that will require evaluation for FDA approval, will be considered.
The subsidy landscape is responding quickly to the COVID-19 virus and the problems this crisis causes world-wide. A lot of new funding opportunities are being released to assist researchers and companies with their Research and Development activities against COVID-19. We have made an overview of all COVID-19 grants & funding opportunities. Check our COVID-19 Call Overview and stay up-to-date.
A more detailed and tailor-made overviews are available in 3 different products:
- Funding Scan. A summarized overview of funding opportunities for one specific R&D project with a short profile of the researcher or company. This includes a strategy with upcoming funding opportunities for the next year.
- Funding Advice. A detailed description of your company, research group, R&D projects and an overview of the timelines involved in future development. This includes a funding strategy for each project for the next 2 years.
- Funding Plan. A long-term funding strategy taking into consideration multiple R&D pillars. This detailed strategy focuses on multiple sources of funding and addresses financial weaknesses in continuing strategic planning.
Read more about it on our Strategic Funding Advice page.